Serum Uric Acid Concentrations and Risk of Adverse Outcomes in Patients with COVID-19
ORIGINAL RESEARCH published: 06 May 2021 doi: 10.3389/fendo.2021.633767 Serum Uric Acid Concentrations and Risk of Adverse Outcomes in Patients With COVID-19 † † † † † Bo Chen 1 , Chenyang Lu 1 , Hong-Qiu Gu 2,3 , Yang Li 4 , Guqin Zhang 5 , Jonathan Lio 6, Xiongyan Luo 1, Lingshu Zhang 1, Yidan Hu 1, Xiaomeng Lan 7, Zerong Chen 7, Qibing Xie 1* and Huaqin Pan 8,9,10* 1 Department of Rheumatology and Immunology, West China Hospital, Sichuan University, Chengdu, China, 2 China National Clinical Research Center for Neurological Diseases, Beijing Tiantan Hospital, Capital Medical University, Beijing, China, 3 National Center for Healthcare Quality Management in Neurological Diseases, Beijing Tiantan Hospital, Capital Medical University, Beijing, China, 4 Department of Endocrinology, West China Hospital, Sichuan University, Chengdu, China, 5 Department of Respiratory and Critical Care Medicine, Zhongnan Hospital of Wuhan University, Wuhan, China, 6 Internal Medicine, University of Chicago, Chicago, IL, United States, 7 West China School of Public Health and West China Fourth Hospital, Sichuan University, Chengdu, China, 8 Department of Critical Care Medicine, Zhongnan Hospital of Wuhan University, Wuhan, China, 9 Department of Critical Care Medicine, Leishenshan Hospital, Wuhan, China, 10 Clinical Research Edited by: Center of Hubei Critical Care Medicine, Wuhan, China Jeff M. P. Holly, University of Bristol, United Kingdom Background: Although hyperuricemia frequently associates with respiratory diseases, Reviewed by: Yu Sun, patients with severe coronavirus disease 2019 (COVID-19) and severe acute respiratory Shandong University, China syndrome (SARS) can show marked hypouricemia. Previous studies on the association of Ma. Cecilia Opazo, Andres Bello University, Chile serum uric acid with risk of adverse outcomes related to COVID-19 have produced *Correspondence: contradictory results.
[Show full text]